title: Utilization of cholesterol-rich lipoproteins by perfused rat adrenals.
abstract: This study describes high density lipoprotein (HDL) uptake in the rat adrenal using a newly developed nonrecycling perfusion technique to control both the quality and quantity of the supplied lipoprotein. The aim of the study was to quantify a nonendocytic (alternative) pathway in the delivery of HDL-cholesterol. All experiments were conducted using an acute lipoprotein-deficient rat model (24 h 4-aminopyrazolo-[3, 4-d]-pyrimidine, 4-APP) in which circulating levels of cholesterol were reduced by one half, but various adrenal gland measurements of cholesterol metabolism were unchanged. Both rat HDL (rHDL) and affinity-purified human HDL3 (hHDL3) were used throughout the study. Microscopic autoradiographs (ARGs) indicate that both ligands bind avidly and exclusively to cells of the adrenal fasciculata and reticularis zones. Despite differences in binding affinity, both ligands deliver approximately the same total cholesterol to the cell interior as estimated by double-labeled residualizing tags on HDL (i.e., 125I-labeled dilactitol tyramine-[3H]cholesteryl linoleyl ether (DTT-CLE) HDL). The internalized cholesterol can account for much of the corticosterone produced during the 90-min time frame; however, only a small fraction of this cholesterol could have been provided via the endocytic pathway. Data obtained with the use of 125I-labeled DTT-[3H]CLE-HDL show that only 8.0% (or 0.7%) of corticosterone produced with rHDL (or hHDL3) could have come from cholesterol internalized as a component of intact HDL (i.e., via the endocytic pathway). These calculations strengthen the electron microscopy autoradiographic data that show that few exposed silver grains (representing the localization of the 125I-isotope) are found within the cell cytoplasm. Thus, despite differences in the uptake characteristics of the two ligands, most of the HDL-cholesterol internalized and used for corticosterone production during adrenal perfusion apparently comes from a pathway in which intact HDL are not internalized.
authors.affiliation: Department of Medicine, Stanford University School of Medicine, CA.
authors.forename: S
authors.initials: S
authors.lastname: Azhar
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: E
authors.initials: E
authors.lastname: Reaven
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000311:Adrenal Glands / Q000378:metabolism*; D000818:Animals; D001345:Autoradiography; D002462:Cell Membrane / Q000378:metabolism; D002784:Cholesterol / Q000031:analogs & derivatives / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism*; D003345:Corticosterone / Q000378:metabolism; D006801:Humans; D008297:Male; D008854:Microscopy, Electron; D010477:Perfusion; D051381:Rats; D011919:Rats, Inbred Strains; D014018:Tissue Distribution; D014439:Tyramine / Q000031:analogs & derivatives / Q000378:metabolism
chemical_list: D008076:Cholesterol, HDL; C004420:4-aminopyrazolo(3,4-d)pyrimidine; C027575:cholesteryl linoleyl ether; D002784:Cholesterol; C049133:dilactitol tyramine; D000225:Adenine; D003345:Corticosterone; D014439:Tyramine